On April 26, 2010, New York Medicaid implemented a new cost containment initiative which promotes the use of certain multi-source brand name drugs when the cost of the brand name drug is less expensive than the generic equivalent.

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription
- have a generic copayment;
- will be paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (neither the SMAC nor FUL will be applied);

**IMPORTANT BILLING INFORMATION**

- Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense As Written/Product Selection Code of ‘1’; and
- **Pharmacies can submit any valid NCPDP field (408-D8) value.**

Effective February 10, 2012, Combivir will be added to the dispense brand when less expensive program.

*Current list of Brand name drugs included in this program* *(Date Revised 2/10/2012):*

- Adderall XR
- Arixtra
- Astelin
- Carbatrol
- Combivir
- Concerta
- Diastat
- Kadian
- Lipitor
- Lovenox
- Nasacort AQ
- Uroxatral
- Valtrex
- Zyprexa tablet

* List is subject to change

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs; again promoting the use of the most cost-effective product.